Generic drug companyTeva Pharmaceuticals (Nasdaq: TEVA - News) has had an up-and-down ride for the last few weeks. Thursday Teva reported third-quarter earnings of $0.38, $0.03 better than the analysts’ consensus of $0.35. Revenues rose 53% year over year to $1.25 billion, which topped the $1.19 consensus. More good news: Management raised earnings guidance from $1.35-1.37 to $1.43-1.44 and nudged up revenue guidance slightly. So naturally in the face of all that good news the stock dropped by $0.22 in Thursday trade.
